Manufacturer record

Unigrow Pharmaceuticals: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

2 batches manufactured by Unigrow Pharmaceuticals (Himachal Pradesh) were declared Not of Standard Quality between July 2024 and April 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

2 records linked to Unigrow Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
2Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Jul 2024 to Apr 2025

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

2
NSQ batches since 2024
2
Products affected
Assay
Most common failure
Apr 2025
Latest alert

Flagged batches per year

2024 · 12025 · 1

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Telmisartan & Amlodipine Tablets IP UGT24G06AMfg 2024-10 · Exp 2026-09 It fails the tests for ?Assay? of Amlodipine and ?Dissolution? as specified in the Laboratory Protocol as per IPAssay DTL ThiruvananthapuramState lab Apr 2025
Ofloxacin & Ornidazole Tablets IP (Samri-OZ) UGT23J14AMfg 2023-01 · Exp 2024-12 Dissolution & AssayAssay CDL KolkataCDSCO lab Jul 2024

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.